Please ensure Javascript is enabled for purposes of website accessibility

Fauci: Coronavirus Vaccine Likely Not "Widely Available" Until Several Months Into 2021

By Eric Volkman – Jul 24, 2020 at 7:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The good doctor is somewhat less optimistic than the leading coronavirus vaccine developers about timing.

Ever the voice of caution through the current pandemic, Dr. Anthony Fauci on Friday dampened enthusiasm that an effective and approved coronavirus vaccine is only months away.

Instead, he said during an interview with Washington Post journalist Bob Costa on Friday, "I think as we get into 2021, several months in, that you would have vaccine that would be widely available to people in the United States."

Anthony Fauci.

Image source: National Institute of Allergy and Infectious Diseases.

Certain companies, including ambitious biotech Moderna (MRNA -2.94%), are making good time putting their vaccine candidates through clinical trials. Yet Fauci, the high-profile director of the National Institute of Allergy and Infectious Diseases, doubts that even efforts such as Moderna's will yield a vaccine that will go into use by the end of 2020.

"I'm a little skeptical about that, but, you know, anything is possible," he said.

Fauci's skepticism is based on the processes vaccines have to undergo before coming to market, including comprehensive testing in phase 3 trials and regulatory review. Even when the latter is fast-tracked, it can still be a cumbersome process.

Another problem is production; no matter how prepared a manufacturer might be or how efficient its manufacturing partners, it takes time to produce millions of doses of any vaccine or medication -- particularly if it is new.

On Tuesday, executives from Moderna and peer healthcare companies AstraZeneca (AZN 0.58%), Johnson & Johnson (JNJ 0.32%), and Pfizer (PFE 0.64%) testified in a Congressional hearing about their efforts in developing coronavirus vaccines. They expressed optimism that their vaccines might be ready by the end of 2020 or very early next year.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.